Most Read Articles
6 days ago
Patients with coronary artery disease (CAD) treated in a poor Southeast Asian setting appear to have far too high short-term and medium-term mortality rates, according to a study.
08 Jun 2017

Multipoint pacing (MMP) in cardiac resynchronization therapy (CRT) provides significant improvements in left ventricular mechanics and fluid dynamics as compared with biventricular pacing (BiV).

4 days ago
Cognitive impairment appears to be a risk factor for poor adherence to antihypertensive medication among elderly adults without dementia, a recent study has shown.
02 Aug 2018
Intravenous vasodilator therapy confers survival benefits and superior diuretic response in patients with acute heart failure (AHF), provided that systolic (SBP) reduction is <25 percent, according to a posthoc analysis.

Losartan reduces blood pressure in euvolemic hypertension after dialysis

24 Dec 2017
The American Heart Association has lowered the value for diagnosing hypertension to 130/80 from the previous 140/90.

Losartan at 50 mg is effective in reducing blood pressure in patients with postdialysis euvolemic hypertension, a recent study has shown.

Researchers performed a multicentre, randomized, prospective, single-blind trial including 88 postdialysis euvolemic patients with systolic blood pressure >140 mm Hg who were then randomized to receive either standard antihypertensive therapy or losartan alone or in combination with antihypertensives.

In the standard-arm group, blood pressure improved from a predialysis baseline value of 167.5±18.2 to 162.4±10.2 mm Hg after the 12-month follow-up, resulting in a significant drop of 5.1 mm Hg (p=0.003).  In comparison, blood pressure in the losartan group also significantly dropped from 168.65±16.33 mm Hg at baseline to 158.45±10.65 mm Hg after 12 months (difference, 10.23 mm Hg; p<0.001).

On the other hand, postdialysis blood pressure was only significantly improved in the losartan group, with the baseline value of 156.34±13.40 mm Hg dropping to 149.73±10.21 mm Hg after 12 months. The difference of 6.6 mm Hg reached statistical significance (p<0.001).

There were more deaths in the standard arm than in the losartan group (13.6 vs 4.5 percent), resulting in respective survival probabilities of 84 and 95 percent. However, Kaplan-Meier analysis showed no significant difference in survival between the groups.

In terms of adverse events, losartan was found to be related to two cases of hyperkalaemia, four cases of coughs, three cases of dizziness, and one case of dyspepsia.

Finally, simple linear regression showed that diabetes was significantly associated with postdialysis systolic blood pressure in both the standard-arm (p=0.03) and losartan (p=0.02) treatment groups. 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
Patients with coronary artery disease (CAD) treated in a poor Southeast Asian setting appear to have far too high short-term and medium-term mortality rates, according to a study.
08 Jun 2017

Multipoint pacing (MMP) in cardiac resynchronization therapy (CRT) provides significant improvements in left ventricular mechanics and fluid dynamics as compared with biventricular pacing (BiV).

4 days ago
Cognitive impairment appears to be a risk factor for poor adherence to antihypertensive medication among elderly adults without dementia, a recent study has shown.
02 Aug 2018
Intravenous vasodilator therapy confers survival benefits and superior diuretic response in patients with acute heart failure (AHF), provided that systolic (SBP) reduction is <25 percent, according to a posthoc analysis.